Vpr and Vpx are two of the least well understood lentivirus regulatory genes. Previous studies from this investigator's laboratory have demonstrated that Vpr expression in cells dramatically inhibits the activity of the """"""""molecular clock"""""""" that drives the cell cycle. Vpr prevents activation of the Cdc2/cyclin B at the G2/M border in the cell cycle, an event required to initiate the events of M phase. As a result, the HIV-1 infected cells are arrested in G2. By preventing Cdc2 activation, Vpr could block transduction of apoptotic signals to the nucleus. This would increase the life span of infected cells and provide a selective advantage to the virus. The goal of these studies then is to understand the biochemical basis of Vpr and Vpx induced Cdc2 inhibition and to understand the selective advantage that this provides to HIV in vivo. The following specific aims are proposed:
Specific Aim 1 : To understand the biochemical basis by which Vpr and Vpx inhibit Cdc2 activation.
Specific Aim 2 : To determine whether Vpr or Vpx blocks Fas, TNF-alpha or CTL-induced apoptosis.
Specific Aim 3 : To identify a cellular protein that interacts with Vpr.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
7R01CA072149-04
Application #
6031469
Study Section
AIDS and Related Research Study Section 1 (ARRA)
Program Officer
Read-Connole, Elizabeth Lee
Project Start
1996-06-15
Project End
2002-03-31
Budget Start
1999-04-01
Budget End
2002-03-31
Support Year
4
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Salk Institute for Biological Studies
Department
Type
DUNS #
005436803
City
La Jolla
State
CA
Country
United States
Zip Code
92037
di Marzio, P; Mariani, R; Lui, R et al. (2000) Soluble CD40 ligand induces beta-chemokine production by macrophages and resistance to HIV-1 entry. Cytokine 12:1489-95
Nibbs, R J; Yang, J; Landau, N R et al. (1999) LD78beta, a non-allelic variant of human MIP-1alpha (LD78alpha), has enhanced receptor interactions and potent HIV suppressive activity. J Biol Chem 274:17478-83
Mariani, R; Wong, S; Mulder, L C et al. (1999) CCR2-64I polymorphism is not associated with altered CCR5 expression or coreceptor function. J Virol 73:2450-9
Marodon, G; Landau, N R; Posnett, D N (1999) Altered expression of CD4, CD54, CD62L, and CCR5 in primary lymphocytes productively infected with the human immunodeficiency virus. AIDS Res Hum Retroviruses 15:161-71
Liu, R; Zhao, X; Gurney, T A et al. (1998) Functional analysis of the proximal CCR5 promoter. AIDS Res Hum Retroviruses 14:1509-19
Di Marzio, P; Tse, J; Landau, N R (1998) Chemokine receptor regulation and HIV type 1 tropism in monocyte-macrophages. AIDS Res Hum Retroviruses 14:129-38
Cheng-Mayer, C; Liu, R; Landau, N R et al. (1997) Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor. J Virol 71:1657-61
Chen, Z; Zhou, P; Ho, D D et al. (1997) Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry. J Virol 71:2705-14
Connor, R I; Sheridan, K E; Ceradini, D et al. (1997) Change in coreceptor use correlates with disease progression in HIV-1--infected individuals. J Exp Med 185:621-8
Liu, R; Paxton, W A; Choe, S et al. (1996) Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86:367-77